Razi Kebriaei, PhD
Assistant Professor
Outcomes and Translational Sciences
538 Parks Hall
kebriaei.1@osu.edu
Professional Website
Professional Interests
Dr. Kebriaei’s research is focused on treatment of multi-drug resistant bacterial infections. Some examples of the diseases associated with these infections include bacteremia, endocarditis, bone and joint infections and implant associated infections.
Her current work is concentrated on both planktonic and biofilm states of bacteria and novel approaches for combating multi-drug resistant infections. She utilizes various classes of antimicrobials with distinct mechanisms of action to discover optimal treatment options for a wide range of infectious diseases. In addition, she designs and operates pharmacokinetic/pharmacodynamic models to simulate humanized doses in vitro. The majority of knowledge achieved from this research is translatable to bedside and leads to better patient outcomes.
Her current work is concentrated on both planktonic and biofilm states of bacteria and novel approaches for combating multi-drug resistant infections. She utilizes various classes of antimicrobials with distinct mechanisms of action to discover optimal treatment options for a wide range of infectious diseases. In addition, she designs and operates pharmacokinetic/pharmacodynamic models to simulate humanized doses in vitro. The majority of knowledge achieved from this research is translatable to bedside and leads to better patient outcomes.
Publications
- Editorial: Antibiotics Special Issue on Pharmacokinetic/Pharmacodynamic Models of Antibiotics, Antibiotics. 2022 Nov | journal-article. doi: 10.3390/antibiotics11111540.
- Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative Bacterium Streptococcus mitis/oralis: Bactericidal Effects and Prevention of Daptomycin Resistance In Vitro and In an Ex Vivo Model, Antibiotics. 2022 Oct | journal-article. doi: 10.3390/antibiotics11101409.
- Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility, Antibiotics. 2022 Aug | journal-article. doi: 10.3390/antibiotics11091175.
- Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-Embedded MDR Enterococcus faecium, Antibiotics. 2022 Mar | journal-article. doi: 10.3390/antibiotics11030392.
- The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy, Antibiotics. 2020 Oct | journal-article. doi: 10.3390/antibiotics9110762.
- Combinations of (lipo)glycopeptides with beta-lactams against MRSA: susceptibility insights, Journal of Antimicrobial Chemotherapy. 2020 Jan | journal-article. doi: 10.1093/JAC/DKAA237.
- Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus beta-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium, The Journal of Infectious Diseases. 2020 Jan | journal-article. doi: 10.1093/INFDIS/JIAA319.
- Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model, Antimicrobial Agents and Chemotherapy. 2019 Jan | journal-article. doi: 10.1128/AAC.01743-18.
- Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model, Antimicrobial Agents and Chemotherapy. 2019 Jan | journal-article. doi: 10.1128/AAC.00386-19.
- Evaluation of dalbavancin alone and in combination with beta-lactam antibiotics against resistant phenotypes of Staphylococcus aureus, Journal of Antimicrobial Chemotherapy. 2019 Jan | journal-article. doi: 10.1093/JAC/DKY376.
- Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy. 2019 Jan | journal-article. doi: 10.1128/AAC.00779-19.
- Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin, Infectious Diseases and Therapy. 2019 Jan | journal-article. doi: 10.1007/S40121-019-0239-0.
- Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations, Antimicrobial Agents and Chemotherapy. 2018 Jan | journal-article. doi: 10.1128/AAC.00101-18.
- Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA, Materials. 2018 Jan | journal-article. doi: 10.3390/MA11071245.
- Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with beta-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions, Antimicrobial Agents and Chemotherapy. 2018 Jan | journal-article. doi: 10.1128/AAC.00315-18.
- Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with beta-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions, Antimicrobial Agents and Chemotherapy. 2018 Jan | journal-article. doi: 10.1128/AAC00315-18;E00315-18.
- DROPLET FREQUENCY SENSOR: A NEW MODALITY FOR SENSITIVE, LABEL-FREE, INLINE BIOCHEMICAL DETECTION, TRANSDUCERS - International Solid-State Sensors, Actuators and Microsystems Conference. 2017 Jan | conference-paper. doi: 10.1109/TRANSDUCERS.2017.7994131.